Brittany J Holmes, MD
Pathology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Holmes’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A136529 · Current
Licensed to practise in California · since 2015 · expires 2027-04-30 · Vanderbilt University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$104,948
Medicare paid this office $104,948 for 766 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Evaluation of fine needle aspirate with interpretation and report | 246 | $22,049 | $62 |
| Pathology examination of tissue using a microscope, intermediate complexity | 384 | $18,595 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 136 | $15,928 | $25 |
| Cell examination of specimen, selective cellular enhancement technique | 245 | $6,389 | $24 |
| Pathology examination of tissue using a microscope, moderately high complexity | 37 | $6,079 | $74 |
See all 22 services
| Evaluation of fine needle aspirate with interpretation and report | 246 | $22,049 | $62 |
| Pathology examination of tissue using a microscope, intermediate complexity | 384 | $18,595 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 136 | $15,928 | $25 |
| Cell examination of specimen, selective cellular enhancement technique | 245 | $6,389 | $24 |
| Pathology examination of tissue using a microscope, moderately high complexity | 37 | $6,079 | $74 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 73 | $5,348 | $72 |
| Evaluation of fine needle aspirate | 154 | $5,319 | $31 |
| Special stained specimen slides to examine tissue, initial procedure | 154 | $5,091 | $31 |
| Microscopic genetic analysis of tumor, manual | 67 | $3,692 | $37 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 35 | $2,301 | $64 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 23 | $2,164 | $57 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 54 | $1,784 | $19 |
| Pathology examination of tissue using a microscope, high complexity | 13 | $1,703 | $131 |
| Genetic sequencing localization, initial procedure | 33 | $1,463 | $38 |
| Pathology cytologic examination of specimen during surgery, initial site | 21 | $1,167 | $56 |
| Special stained specimen slides to identify organisms including interpretation and report | 27 | $1,005 | $24 |
| Fine needle aspiration biopsy, first growth | 19 | $872 | $46 |
| Cell examination of specimen, concentration technique | 16 | $343 | $20 |
| Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 11 | $336 | $31 |
| Preparation of tissue for examination by removing any calcium present | 25 | $280 | $11 |
| Special stained specimen slides to examine tissue including interpretation and report | 14 | $226 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 17 | $214 | $10 |
Who their Medicare patients are
766 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 11% · Women 54% · Also on Medicaid 23% · Health risk score 1.70. Above the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 75% · Cancer 39% · Diabetes 34% · Coronary heart disease 32% · Chronic kidney disease 29% · Atrial fibrillation 22% · Heart failure 19% · COPD 19% · Depression 19% · Stroke 10% · Dementia 7%.
The office billed $1,460,338, Medicare allowed $132,612 and paid $104,948; for 2,853 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 766 | 2,853 | 74 | 1.70 | $1,460,338 | $104,948 |
| 2023 | 538 | 1,797 | 74 | 1.84 | $802,555 | $68,378 |
| 2022 | 595 | 2,372 | 74 | 1.67 | $789,070 | $93,347 |
| 2021 | 629 | 2,669 | 74 | 1.46 | $767,838 | $110,184 |
| 2020 | 612 | 2,339 | 72 | 1.78 | $686,269 | $100,967 |
| 2019 | 655 | 2,513 | 73 | 1.84 | $712,489 | $107,473 |
| 2018 | 661 | 2,366 | 73 | 1.77 | $621,326 | $100,126 |
| 2017 | 823 | 2,697 | 73 | 1.67 | $693,578 | $112,780 |
| 2016 | 592 | 1,861 | 73 | 1.70 | $519,838 | $75,431 |
| 2015 | 215 | 644 | 72 | 1.63 | $184,648 | $25,610 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Evaluation of fine needle aspirate with interpretation and report | 164 | $14,914 | $65 |
| Pathology examination of tissue using a microscope, intermediate complexity | 241 | $12,087 | $35 |
| Special stained specimen slides to examine tissue, each additional procedure | 90 | $9,990 | $26 |
| Cell examination of specimen, selective cellular enhancement technique | 199 | $5,452 | $25 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 59 | $4,597 | $78 |
| Evaluation of fine needle aspirate | 98 | $3,728 | $33 |
| Pathology examination of tissue using a microscope, moderately high complexity | 22 | $3,544 | $77 |
| Special stained specimen slides to examine tissue, initial procedure | 97 | $3,213 | $32 |
| Microscopic genetic analysis of tumor, manual | 39 | $2,213 | $39 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 30 | $1,997 | $67 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 27 | $914 | $19 |
| Special stained specimen slides to identify organisms including interpretation and report | 16 | $764 | $25 |
| Genetic sequencing localization, initial procedure | 18 | $723 | $40 |
| Cell examination of specimen, concentration technique | 13 | $261 | $20 |
| Preparation of tissue for examination by removing any calcium present | 13 | $161 | $11 |
2022: 20 services
| Pathology examination of tissue using a microscope, intermediate complexity | 308 | $16,166 | $35 |
| Evaluation of fine needle aspirate with interpretation and report | 172 | $16,164 | $65 |
| Special stained specimen slides to examine tissue, each additional procedure | 113 | $13,388 | $26 |
| Pathology examination of specimen during surgery, first tissue block | 37 | $7,444 | $59 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 72 | $5,512 | $73 |
| Pathology examination of tissue using a microscope, moderately high complexity | 41 | $5,332 | $77 |
| Evaluation of fine needle aspirate | 123 | $4,794 | $33 |
| Special stained specimen slides to examine tissue, initial procedure | 133 | $4,441 | $32 |
| Cell examination of specimen, selective cellular enhancement technique | 162 | $4,217 | $25 |
| Microscopic genetic analysis of tumor, manual | 42 | $2,254 | $39 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 49 | $1,478 | $21 |
| Special stained specimen slides to identify organisms including interpretation and report | 35 | $1,421 | $25 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 17 | $1,373 | $81 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 15 | $1,347 | $59 |
| Genetic sequencing localization, initial procedure | 28 | $1,180 | $41 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 17 | $1,004 | $59 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 12 | $924 | $77 |
| Preparation of tissue for examination by removing any calcium present | 25 | $324 | $12 |
| Cell examination of specimen, concentration technique | 11 | $234 | $21 |
| Pathology examination of tissue using a microscope, moderately low complexity | 15 | $170 | $11 |
2021: 23 services
| Evaluation of fine needle aspirate with interpretation and report | 207 | $17,870 | $66 |
| Pathology examination of tissue using a microscope, intermediate complexity | 339 | $17,308 | $36 |
| Special stained specimen slides to examine tissue, each additional procedure | 130 | $15,168 | $27 |
| Pathology examination of tissue using a microscope, moderately high complexity | 45 | $9,751 | $79 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 101 | $8,103 | $78 |
| Evaluation of fine needle aspirate | 155 | $6,268 | $34 |
| Special stained specimen slides to examine tissue, initial procedure | 170 | $6,190 | $33 |
| Pathology examination of specimen during surgery, first tissue block | 30 | $5,548 | $60 |
| Microscopic genetic analysis of tumor, manual | 79 | $4,285 | $40 |
| Cell examination of specimen, selective cellular enhancement technique | 113 | $3,011 | $26 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 23 | $1,942 | $81 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 23 | $1,895 | $79 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 22 | $1,809 | $60 |
| Special stained specimen slides to identify organisms including interpretation and report | 42 | $1,549 | $24 |
| Fine needle aspiration biopsy, first growth | 32 | $1,494 | $47 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 19 | $1,262 | $66 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 38 | $1,087 | $20 |
| Genetic sequencing localization, initial procedure | 23 | $970 | $40 |
| Pathology cytologic examination of specimen during surgery, initial site | 16 | $953 | $60 |
| Preparation of tissue for examination by removing any calcium present | 31 | $508 | $12 |
| Pathology examination of tissue using a microscope, moderately low complexity | 19 | $303 | $11 |
| Cell examination of specimen, concentration technique | 14 | $301 | $22 |
| Special stained specimen slides to examine tissue including interpretation and report | 11 | $206 | $11 |
2020: 21 services
| Evaluation of fine needle aspirate with interpretation and report | 239 | $21,068 | $69 |
| Pathology examination of tissue using a microscope, intermediate complexity | 333 | $17,084 | $37 |
| Special stained specimen slides to examine tissue, each additional procedure | 120 | $12,272 | $28 |
| Pathology examination of tissue using a microscope, moderately high complexity | 38 | $8,049 | $82 |
| Pathology examination of specimen during surgery, first tissue block | 30 | $6,070 | $62 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 73 | $5,799 | $78 |
| Special stained specimen slides to examine tissue, initial procedure | 143 | $5,587 | $34 |
| Evaluation of fine needle aspirate | 120 | $4,748 | $35 |
| Cell examination of specimen, selective cellular enhancement technique | 155 | $4,319 | $27 |
| Microscopic genetic analysis of tumor, manual | 51 | $2,973 | $41 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 31 | $2,091 | $65 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 23 | $1,873 | $81 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 15 | $1,366 | $85 |
| Fine needle aspiration biopsy, first growth | 28 | $1,362 | $49 |
| Special stained specimen slides to identify organisms including interpretation and report | 22 | $884 | $24 |
| Genetic sequencing localization, initial procedure | 15 | $688 | $43 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 17 | $526 | $22 |
| Preparation of tissue for examination by removing any calcium present | 22 | $352 | $11 |
| Cell examination of specimen, concentration technique | 14 | $308 | $22 |
| Special stained specimen slides to examine tissue including interpretation and report | 14 | $235 | $12 |
| Pathology examination of tissue using a microscope, moderately low complexity | 13 | $177 | $10 |
2019: 19 services
| Evaluation of fine needle aspirate with interpretation and report | 306 | $26,035 | $67 |
| Pathology examination of tissue using a microscope, intermediate complexity | 325 | $16,057 | $36 |
| Special stained specimen slides to examine tissue, each additional procedure | 134 | $15,270 | $28 |
| Pathology examination of specimen during surgery, first tissue block | 28 | $6,966 | $61 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 82 | $6,436 | $78 |
| Pathology examination of tissue using a microscope, moderately high complexity | 28 | $5,527 | $80 |
| Special stained specimen slides to examine tissue, initial procedure | 152 | $5,440 | $34 |
| Cell examination of specimen, selective cellular enhancement technique | 170 | $4,672 | $26 |
| Evaluation of fine needle aspirate | 112 | $4,182 | $34 |
| Microscopic genetic analysis of tumor, manual | 46 | $2,638 | $41 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 22 | $2,188 | $61 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 28 | $1,849 | $66 |
| Special stained specimen slides to identify organisms including interpretation and report | 47 | $1,830 | $25 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 16 | $1,275 | $80 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 15 | $1,248 | $83 |
| Fine needle aspiration biopsy, first growth | 22 | $1,027 | $47 |
| Genetic sequencing localization, initial procedure | 22 | $964 | $42 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 13 | $781 | $60 |
| Preparation of tissue for examination by removing any calcium present | 18 | $272 | $12 |
2018: 21 services
| Evaluation of fine needle aspirate with interpretation and report | 249 | $20,102 | $66 |
| Pathology examination of tissue using a microscope, intermediate complexity | 328 | $15,397 | $36 |
| Special stained specimen slides to examine tissue, each additional procedure | 112 | $11,410 | $27 |
| Pathology examination of tissue using a microscope, moderately high complexity | 35 | $8,799 | $80 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 86 | $6,591 | $77 |
| Pathology examination of specimen during surgery, first tissue block | 34 | $5,895 | $61 |
| Special stained specimen slides to examine tissue, initial procedure | 145 | $5,653 | $34 |
| Cell examination of specimen, selective cellular enhancement technique | 193 | $5,082 | $24 |
| Evaluation of fine needle aspirate | 110 | $4,037 | $35 |
| Microscopic genetic analysis of tumor, manual | 35 | $2,473 | $43 |
| Fine needle aspiration biopsy, first growth | 35 | $2,283 | $62 |
| Special stained specimen slides to identify organisms including interpretation and report | 50 | $2,007 | $25 |
| Fine needle aspiration using imaging guidance | 23 | $1,480 | $57 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 15 | $1,234 | $82 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 13 | $1,197 | $60 |
| Genetic sequencing localization, initial procedure | 22 | $966 | $42 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 12 | $719 | $60 |
| Ultrasonic guidance for needle placement | 21 | $613 | $29 |
| Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening | 13 | $407 | $31 |
| Preparation of tissue for examination by removing any calcium present | 16 | $313 | $12 |
| Special stained specimen slides to examine tissue including interpretation and report | 12 | $225 | $11 |
2017: 22 services
| Evaluation of fine needle aspirate with interpretation and report | 323 | $27,594 | $67 |
| Pathology examination of tissue using a microscope, intermediate complexity | 379 | $17,871 | $36 |
| Special stained specimen slides to examine tissue, each additional procedure | 135 | $11,896 | $27 |
| Cell examination of specimen, selective cellular enhancement technique | 289 | $8,116 | $26 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 90 | $7,254 | $78 |
| Pathology examination of tissue using a microscope, moderately high complexity | 34 | $6,055 | $77 |
| Evaluation of fine needle aspirate | 154 | $5,564 | $34 |
| Special stained specimen slides to examine tissue, initial procedure | 150 | $5,472 | $34 |
| Pathology examination of specimen during surgery, first tissue block | 22 | $4,667 | $60 |
| Fine needle aspiration using imaging guidance | 44 | $2,809 | $57 |
| Special stained specimen slides to identify organisms including interpretation and report | 57 | $2,110 | $26 |
| Pathology examination of tissue using a microscope, high complexity | 12 | $1,844 | $142 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 14 | $1,672 | $60 |
| Microscopic genetic analysis of tumor, manual | 20 | $1,615 | $52 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 19 | $1,582 | $83 |
| Fine needle aspiration biopsy, first growth | 24 | $1,488 | $62 |
| Ultrasonic guidance for needle placement | 42 | $1,196 | $28 |
| Cell examination of specimen, concentration technique | 17 | $409 | $22 |
| Preparation of tissue for examination by removing any calcium present | 20 | $312 | $12 |
| Pathology examination of tissue using a microscope, moderately low complexity | 21 | $298 | $11 |
| Special stained specimen slides to examine tissue including interpretation and report | 14 | $293 | $11 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 12 | $277 | $21 |
2016: 16 services
| Evaluation of fine needle aspirate with interpretation and report | 258 | $20,539 | $65 |
| Pathology examination of tissue using a microscope, intermediate complexity | 239 | $9,993 | $36 |
| Special stained specimen slides to examine tissue, each additional procedure | 78 | $7,537 | $25 |
| Cell examination of specimen, selective cellular enhancement technique | 235 | $6,587 | $25 |
| Evaluation of fine needle aspirate | 135 | $5,092 | $34 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 51 | $4,013 | $77 |
| Special stained specimen slides to examine tissue, initial procedure | 93 | $3,282 | $33 |
| Fine needle aspiration using imaging guidance | 44 | $3,040 | $58 |
| Fine needle aspiration biopsy, first growth | 44 | $2,974 | $62 |
| Special stained specimen slides to identify organisms including interpretation and report | 39 | $1,593 | $26 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 15 | $1,527 | $102 |
| Ultrasonic guidance for needle placement | 42 | $1,260 | $30 |
| Genetic sequencing localization, initial procedure | 13 | $498 | $38 |
| Cell examination of specimen, concentration technique | 14 | $301 | $22 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 11 | $276 | $21 |
| Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening | 13 | $264 | $20 |
2015: 10 services
| Evaluation of fine needle aspirate with interpretation and report | 96 | $8,480 | $66 |
| Pathology examination of tissue using a microscope, intermediate complexity | 92 | $4,061 | $36 |
| Cell examination of specimen, selective cellular enhancement technique | 108 | $2,939 | $26 |
| Evaluation of fine needle aspirate | 45 | $1,879 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 25 | $1,625 | $20 |
| Fine needle aspiration biopsy, first growth | 20 | $1,548 | $62 |
| Special stained specimen slides to examine tissue, initial procedure | 27 | $967 | $33 |
| Fine needle aspiration using imaging guidance | 12 | $884 | $59 |
| Special stained specimen slides to identify organisms including interpretation and report | 15 | $482 | $25 |
| Ultrasonic guidance for needle placement | 12 | $357 | $30 |
Medicaid work
$8,427 in 2024
Medicaid paid $8,427 for 303 billed services this clinician did in 2024, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 211 | $6,278 |
| Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal | 78 | $1,594 |
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 14 | $556 |
| 2024 | 303 | 3 | 24 | $8,427 |
| 2023 | 120 | 2 | 22 | $3,680 |
| 2022 | 177 | 4 | 23 | $5,579 |
| 2021 | 91 | 3 | 18 | $2,851 |
| 2020 | 181 | 3 | 20 | $4,929 |
| 2019 | 159 | 3 | 20 | $4,928 |
| 2018 | 147 | 2 | 19 | $5,120 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 72 | $2,816 |
| Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal | 48 | $864 |
2022
| TISSUE EXAM BY PATHOLOGIST | 138 | $4,759 |
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 15 | $532 |
| Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site | 12 | $193 |
| Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal | 12 | $95 |
2021
| TISSUE EXAM BY PATHOLOGIST | 63 | $1,686 |
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 16 | $877 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 12 | $288 |
2020
| TISSUE EXAM BY PATHOLOGIST | 130 | $3,458 |
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 34 | $1,158 |
| Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal | 17 | $313 |
2019
| TISSUE EXAM BY PATHOLOGIST | 86 | $2,541 |
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 61 | $2,186 |
| Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site | 12 | $202 |
2018
| TISSUE EXAM BY PATHOLOGIST | 101 | $3,177 |
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 46 | $1,943 |
Money from drug and device companies
$23 in 2023
A payment is not proof that care is biased.
| Hologic Sales and Service | Thinprep 2000 Processor | $23 | 1 payment
|
See the published payment
| Hologic Sales and Service | Meals · 2023-06-07 | Thinprep 2000 Processor | $23 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1972827475
- Licence
- CA A136529California A136529: Current · expires 2027-04-30
- Trained
- Vanderbilt University School of Medicine, 2010
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZC0500X (207ZC0500X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2010-03-26
- NPI last updated
- 2024-03-13
- NPI record certified
- 2024-03-13
This is when the NPI record was last certified, not a medical board exam.